Following health news with a useful perspective requires going beyond the stream of news reports. Here, we offer an analysis focused on pharmacovigilance, supply issues, and epidemiological data, three areas where reliable information is most lacking.
GLP-1 Analogues: Decoding the Pharmacovigilance Signal from ANSM
ANSM has launched an investigation into the misuse of anti-obesity treatments such as GLP-1 analogues, covering the period from February 2025 to January 2026. The report lists several dozen reports of misuse, with about half classified as serious cases, including several acute pancreatitis cases.
Misuse is the real issue. Patients are accessing these molecules outside the prescription framework, sometimes through non-pharmaceutical channels, with the goal of weight loss. ANSM reminds that dispensing must go through a medical prescription, a pharmacy delivery, and regular clinical follow-up.
To follow the evolution of these alerts, it is possible to find information on Santé 365 regarding the pharmacovigilance of these treatments.
The media pressure surrounding these molecules accelerates off-label prescriptions. We observe that the signal identified by ANSM should lead to strengthened controls at every stage of the dispensing chain.
Fluoxetine 20 mg: Supply Tensions and Consequences in Pharmacies
In early October 2026, temporary production difficulties affecting fluoxetine 20 mg were reported by the National Order of Pharmacists. ANSM has asked laboratories to mobilize their stocks and increase their supplies.
A shortage of a selective serotonin reuptake inhibitor is not trivial. A sudden stop causes withdrawal syndrome: dizziness, irritability, sensory disturbances. Community pharmacists are on the front line managing substitutions and partial renewals.
Structural Fragility of European Production
Supply tensions are no longer limited to niche treatments. They now affect high-turnover generics, revealing a vulnerability in the European manufacturing of active ingredients.
ANSM is working on extending the shelf life of certain medications. The goal: to reduce pharmaceutical waste and decrease pressure on production lines. For molecules with a short shelf life, this measure would have a direct effect on availability in pharmacies.
Cholera: What the Divergence Between Reported Cases and Lethality Reveals According to WHO
The global cholera report published by WHO in September 2026 presents a data point that deserves technical scrutiny: lethality increased in 2025 while the number of reported cases declined.
Two hypotheses combine. A decrease in reported cases may indicate a real reduction in transmission, but also a deterioration in surveillance in endemic areas. When cases are detected at a more advanced stage, lethality mechanically increases.
Implications for Vaccination Recommendations in France
Endemic cholera does not directly affect France. However, this data impacts vaccination recommendations for travelers and the international allocation of oral vaccines.
- The increase in lethality reflects late access to rehydration care in the affected countries, without necessarily indicating increased virulence of the bacterium.
- The global stock of oral cholera vaccines remains limited, and prioritization is based on these epidemiological reports.
- Travel medicine professionals must integrate these updates into their pre-departure consultations, particularly for Sub-Saharan Africa and Southeast Asia.
Prevention and Screening: Adapting Monitoring to Available Sources
The prevention assessments offered by Health Insurance now target specific age groups with appropriate examinations. Screening aims to detect a pathology before the first symptoms, fundamentally separating it from curative care.
We recommend distinguishing three levels in health information accessible online:
- Institutional sources (ANSM, HAS, Health Insurance) publish validated data, but with sometimes long update delays.
- Mainstream media disseminate alerts quickly, often at the cost of oversimplifying pharmacological or epidemiological nuances.
- Specialized sites offer thematic monitoring (pharmacovigilance, clinical trials, stock shortages) with a higher level of detail.
A pharmacovigilance signal on GLP-1 analogues, a supply tension on fluoxetine, and a WHO report on cholera fall under three distinct information circuits. Cross-referencing them requires active and methodical monitoring.
The most useful health information is measured by its ability to inform a concrete decision: renewing a treatment despite a supply tension, assessing the relevance of a vaccine before travel, or identifying misuse reported by health authorities.
